Deutsche Bank
CYCN icon

Deutsche Bank’s Cyclerion Therapeutics CYCN Stock Holding History

Deutsche Bank’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-3,295
Closed -$257K – 4440
2021
Q2 		$257K Sell
3,295
-759
-19% -$47.5K ﹤0.01% 3639
2021
Q1 		$226K Buy
4,054
+3,268
+416% +$245K ﹤0.01% 3569
2020
Q4 		$48K Buy
786
+193
+33% +$13.2K ﹤0.01% 4121
2020
Q3 		$72K Buy
593
+53
+10% +$6.06K ﹤0.01% 3697
2020
Q2 		$64K Buy
540
+119
+28% +$9.95K ﹤0.01% 3685
2020
Q1 		$23K Sell
421
-26
-6% -$1.85K ﹤0.01% 3874
2019
Q4 		$23K Buy
447
+86
+24% +$8.03K ﹤0.01% 4254
2019
Q3 		$87K Sell
361
-549
-60% -$119K ﹤0.01% 3622
2019
Q2 		$207K Buy
+910
New +$258K ﹤0.01% 3803

Other funds holding CYCN

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deutsche Bank's CYCN Position: Q3 2021 in Review

Deutsche Bank sold out of Cyclerion Therapeutics (CYCN) in Q3 2021, closing a stake of 3,295 shares — an estimated $257K sold.

Deutsche Bank first reported a position in CYCN in Q2 2019 and held it in 9 quarters. The position peaked at $257K in Q2 2021. 61 funds tracked by Wall St. Rank hold CYCN as of Q3 2021.

  • Deutsche Bank reported no remaining Cyclerion Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Deutsche Bank sold 3,295 Cyclerion Therapeutics shares in Q3 2021, an estimated $257K.
  • Deutsche Bank first reported a position in Cyclerion Therapeutics in Q2 2019 and held it in 9 quarters.
  • Deutsche Bank's Cyclerion Therapeutics position peaked at $257K in Q2 2021.
  • 61 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q3 2021.

Based on Deutsche Bank's 13F filing for Q3 2021, filed 4 Nov 2021.